Serum anti-lipocalin 2 IgG is a novel biomarker in the diagnosis of systemic lupus erythematosus

Y. N. Li, F. L. Hu, Y. J. Dai, R. Li, X. X. Ma, Y. Du, M. Feng, Y. Jia, C. F. Zhang, L. Zhu, Dana Ascherman, Z. G. Li

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background: Previous work suggests that lipocalin 2 is involved in the pathogenesis of systemic lupus erythematosus (SLE) and that this novel antigen could serve as a high-quality renal biomarker of acute kidney injury in SLE. However, serum lipocalin 2 antibody levels remain unclear. We have therefore undertaken this study to assess the level of serum IgG antibody against lipocalin 2 in different disease states and to evaluate the diagnostic value of this potential biomarker in SLE. Methods: Serum levels of anti-lipocalin IgG antibodies were measured by ELISA in 103 SLE patients, 93 rheumatoid arthritis (RA) patients, 29 primary Sjö gren's syndrome (pSS) patients, 13 systemic sclerosis (SSc) patients, and 91 healthy controls. Diagnostic properties of anti-lipocalin IgG were determined by receiver-operating characteristic (ROC) curve analysis. Results: The level of serum anti-lipocalin IgG in patients with SLE was significantly higher than in patients with RA, pSS, SSc, or healthy controls (p<0.05), effectively distinguishing SLE from other conditions with high sensitivity and specificity (49.5% and 90.7%, respectively). In ROC curve analysis, the area under the curve (AUC) is 0.783, with a 95% confidence interval (CI) extending from 0.729 to 0.839. Antilipocalin antibodies were present in 48.1% of anti-Sm-negative SLE patients, and also occurred in SLE patients lacking anti-dsDNA (52%) or anti-nucleosome antibodies (46.3%) antibodies. Finally, SLE patients with positive anti-lipocalin IgG possessed higher levels of IgA and CRP than the negative group (p<0.05), clearly demonstrating a positive correlation between anti-lipocalin IgG and these laboratory parameters. Conclusions: Antilipocalin 2 IgG is a promising biomarker for the diagnosis of SLE, particularly when obtained in conjunction with anti-Sm, anti-dsDNA, and anti-nucleosome antibody levels.

Original languageEnglish
Pages (from-to)868-875
Number of pages8
JournalLupus
Volume23
Issue number9
DOIs
StatePublished - Jan 1 2014

Fingerprint

Systemic Lupus Erythematosus
Immunoglobulin G
Biomarkers
Lipocalins
Serum
Antibodies
Nucleosomes
Systemic Scleroderma
ROC Curve
Anti-Idiotypic Antibodies
Rheumatoid Arthritis
Lipocalin-2
Acute Kidney Injury
Immunoglobulin A
Area Under Curve
Enzyme-Linked Immunosorbent Assay
anti-IgG
Confidence Intervals
Kidney
Antigens

Keywords

  • anti-lipocalin IgG
  • Lipocalin 2
  • neutrophil gelatinasea-associated lipocalin (NGAL)
  • ROC curve
  • systemic lupus erythematosus (SLE)

ASJC Scopus subject areas

  • Rheumatology

Cite this

Li, Y. N., Hu, F. L., Dai, Y. J., Li, R., Ma, X. X., Du, Y., ... Li, Z. G. (2014). Serum anti-lipocalin 2 IgG is a novel biomarker in the diagnosis of systemic lupus erythematosus. Lupus, 23(9), 868-875. https://doi.org/10.1177/0961203314530484

Serum anti-lipocalin 2 IgG is a novel biomarker in the diagnosis of systemic lupus erythematosus. / Li, Y. N.; Hu, F. L.; Dai, Y. J.; Li, R.; Ma, X. X.; Du, Y.; Feng, M.; Jia, Y.; Zhang, C. F.; Zhu, L.; Ascherman, Dana; Li, Z. G.

In: Lupus, Vol. 23, No. 9, 01.01.2014, p. 868-875.

Research output: Contribution to journalArticle

Li, YN, Hu, FL, Dai, YJ, Li, R, Ma, XX, Du, Y, Feng, M, Jia, Y, Zhang, CF, Zhu, L, Ascherman, D & Li, ZG 2014, 'Serum anti-lipocalin 2 IgG is a novel biomarker in the diagnosis of systemic lupus erythematosus', Lupus, vol. 23, no. 9, pp. 868-875. https://doi.org/10.1177/0961203314530484
Li, Y. N. ; Hu, F. L. ; Dai, Y. J. ; Li, R. ; Ma, X. X. ; Du, Y. ; Feng, M. ; Jia, Y. ; Zhang, C. F. ; Zhu, L. ; Ascherman, Dana ; Li, Z. G. / Serum anti-lipocalin 2 IgG is a novel biomarker in the diagnosis of systemic lupus erythematosus. In: Lupus. 2014 ; Vol. 23, No. 9. pp. 868-875.
@article{e322c7f721714361bd34535179a5eb8e,
title = "Serum anti-lipocalin 2 IgG is a novel biomarker in the diagnosis of systemic lupus erythematosus",
abstract = "Background: Previous work suggests that lipocalin 2 is involved in the pathogenesis of systemic lupus erythematosus (SLE) and that this novel antigen could serve as a high-quality renal biomarker of acute kidney injury in SLE. However, serum lipocalin 2 antibody levels remain unclear. We have therefore undertaken this study to assess the level of serum IgG antibody against lipocalin 2 in different disease states and to evaluate the diagnostic value of this potential biomarker in SLE. Methods: Serum levels of anti-lipocalin IgG antibodies were measured by ELISA in 103 SLE patients, 93 rheumatoid arthritis (RA) patients, 29 primary Sj{\"o} gren's syndrome (pSS) patients, 13 systemic sclerosis (SSc) patients, and 91 healthy controls. Diagnostic properties of anti-lipocalin IgG were determined by receiver-operating characteristic (ROC) curve analysis. Results: The level of serum anti-lipocalin IgG in patients with SLE was significantly higher than in patients with RA, pSS, SSc, or healthy controls (p<0.05), effectively distinguishing SLE from other conditions with high sensitivity and specificity (49.5{\%} and 90.7{\%}, respectively). In ROC curve analysis, the area under the curve (AUC) is 0.783, with a 95{\%} confidence interval (CI) extending from 0.729 to 0.839. Antilipocalin antibodies were present in 48.1{\%} of anti-Sm-negative SLE patients, and also occurred in SLE patients lacking anti-dsDNA (52{\%}) or anti-nucleosome antibodies (46.3{\%}) antibodies. Finally, SLE patients with positive anti-lipocalin IgG possessed higher levels of IgA and CRP than the negative group (p<0.05), clearly demonstrating a positive correlation between anti-lipocalin IgG and these laboratory parameters. Conclusions: Antilipocalin 2 IgG is a promising biomarker for the diagnosis of SLE, particularly when obtained in conjunction with anti-Sm, anti-dsDNA, and anti-nucleosome antibody levels.",
keywords = "anti-lipocalin IgG, Lipocalin 2, neutrophil gelatinasea-associated lipocalin (NGAL), ROC curve, systemic lupus erythematosus (SLE)",
author = "Li, {Y. N.} and Hu, {F. L.} and Dai, {Y. J.} and R. Li and Ma, {X. X.} and Y. Du and M. Feng and Y. Jia and Zhang, {C. F.} and L. Zhu and Dana Ascherman and Li, {Z. G.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1177/0961203314530484",
language = "English",
volume = "23",
pages = "868--875",
journal = "Lupus",
issn = "0961-2033",
publisher = "SAGE Publications Ltd",
number = "9",

}

TY - JOUR

T1 - Serum anti-lipocalin 2 IgG is a novel biomarker in the diagnosis of systemic lupus erythematosus

AU - Li, Y. N.

AU - Hu, F. L.

AU - Dai, Y. J.

AU - Li, R.

AU - Ma, X. X.

AU - Du, Y.

AU - Feng, M.

AU - Jia, Y.

AU - Zhang, C. F.

AU - Zhu, L.

AU - Ascherman, Dana

AU - Li, Z. G.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Background: Previous work suggests that lipocalin 2 is involved in the pathogenesis of systemic lupus erythematosus (SLE) and that this novel antigen could serve as a high-quality renal biomarker of acute kidney injury in SLE. However, serum lipocalin 2 antibody levels remain unclear. We have therefore undertaken this study to assess the level of serum IgG antibody against lipocalin 2 in different disease states and to evaluate the diagnostic value of this potential biomarker in SLE. Methods: Serum levels of anti-lipocalin IgG antibodies were measured by ELISA in 103 SLE patients, 93 rheumatoid arthritis (RA) patients, 29 primary Sjö gren's syndrome (pSS) patients, 13 systemic sclerosis (SSc) patients, and 91 healthy controls. Diagnostic properties of anti-lipocalin IgG were determined by receiver-operating characteristic (ROC) curve analysis. Results: The level of serum anti-lipocalin IgG in patients with SLE was significantly higher than in patients with RA, pSS, SSc, or healthy controls (p<0.05), effectively distinguishing SLE from other conditions with high sensitivity and specificity (49.5% and 90.7%, respectively). In ROC curve analysis, the area under the curve (AUC) is 0.783, with a 95% confidence interval (CI) extending from 0.729 to 0.839. Antilipocalin antibodies were present in 48.1% of anti-Sm-negative SLE patients, and also occurred in SLE patients lacking anti-dsDNA (52%) or anti-nucleosome antibodies (46.3%) antibodies. Finally, SLE patients with positive anti-lipocalin IgG possessed higher levels of IgA and CRP than the negative group (p<0.05), clearly demonstrating a positive correlation between anti-lipocalin IgG and these laboratory parameters. Conclusions: Antilipocalin 2 IgG is a promising biomarker for the diagnosis of SLE, particularly when obtained in conjunction with anti-Sm, anti-dsDNA, and anti-nucleosome antibody levels.

AB - Background: Previous work suggests that lipocalin 2 is involved in the pathogenesis of systemic lupus erythematosus (SLE) and that this novel antigen could serve as a high-quality renal biomarker of acute kidney injury in SLE. However, serum lipocalin 2 antibody levels remain unclear. We have therefore undertaken this study to assess the level of serum IgG antibody against lipocalin 2 in different disease states and to evaluate the diagnostic value of this potential biomarker in SLE. Methods: Serum levels of anti-lipocalin IgG antibodies were measured by ELISA in 103 SLE patients, 93 rheumatoid arthritis (RA) patients, 29 primary Sjö gren's syndrome (pSS) patients, 13 systemic sclerosis (SSc) patients, and 91 healthy controls. Diagnostic properties of anti-lipocalin IgG were determined by receiver-operating characteristic (ROC) curve analysis. Results: The level of serum anti-lipocalin IgG in patients with SLE was significantly higher than in patients with RA, pSS, SSc, or healthy controls (p<0.05), effectively distinguishing SLE from other conditions with high sensitivity and specificity (49.5% and 90.7%, respectively). In ROC curve analysis, the area under the curve (AUC) is 0.783, with a 95% confidence interval (CI) extending from 0.729 to 0.839. Antilipocalin antibodies were present in 48.1% of anti-Sm-negative SLE patients, and also occurred in SLE patients lacking anti-dsDNA (52%) or anti-nucleosome antibodies (46.3%) antibodies. Finally, SLE patients with positive anti-lipocalin IgG possessed higher levels of IgA and CRP than the negative group (p<0.05), clearly demonstrating a positive correlation between anti-lipocalin IgG and these laboratory parameters. Conclusions: Antilipocalin 2 IgG is a promising biomarker for the diagnosis of SLE, particularly when obtained in conjunction with anti-Sm, anti-dsDNA, and anti-nucleosome antibody levels.

KW - anti-lipocalin IgG

KW - Lipocalin 2

KW - neutrophil gelatinasea-associated lipocalin (NGAL)

KW - ROC curve

KW - systemic lupus erythematosus (SLE)

UR - http://www.scopus.com/inward/record.url?scp=84903766456&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903766456&partnerID=8YFLogxK

U2 - 10.1177/0961203314530484

DO - 10.1177/0961203314530484

M3 - Article

VL - 23

SP - 868

EP - 875

JO - Lupus

JF - Lupus

SN - 0961-2033

IS - 9

ER -